Beijing Deli Furui Pharmaceutical Technology Co. Ltd.

Primary Objective: This study used a randomized, open-label, four-sequence, four-period, fasting and fed dosing design to compare the exposure of celecoxib tablets (I) developed by Beijing Delishena Pharmaceutical Technology Co., Ltd. and manufactured by Anhui Sihuan Kebao Pharmaceutical Co., Ltd., and celecoxib capsules (Celebrex®) manufactured by Pfizer Pharmaceuticals LLC, under fasting and fed conditions in healthy volunteers. The food effect of celecoxib tablets (I) and celecoxib capsules under fasting and fed conditions was also evaluated. Secondary Objective: To observe the safety of a single oral dose of the test drug and the control drug in healthy volunteers.

Main purpose: This study used a randomized open, four-sequence, four-period, fasting and postprandial dosing design to compare the differences in exposure of 2 tablets of celecoxib tablets (I) (60 mg/tablet) developed by Beijing Delishena Pharmaceutical Technology Co., Ltd. and produced by Anhui Sihuan Kebao Pharmaceutical Co., Ltd. and 1 tablet of celecoxib capsules (200 mg/capsule, Celebrex®) produced by Pfizer Pharmaceuticals LLC in healthy subjects under fasting and postprandial conditions. The food effects of celecoxib tablets (I) and celecoxib capsules under fasting/postprandial conditions were evaluated respectively. Secondary purpose: To observe the safety of single oral administration of test drugs and control drugs in healthy volunteers.